Swedish Orphan Biovitrum AB (publ)
STO:SOBI
SOBI's latest stock split occurred on Aug 28, 2023
The company executed a 290-for-277 stock split, meaning that for every 277 shares held, investors received 290 new shares.
Before the split, SOBI traded at 211.475 per share. Afterward, the share price was about 209.4.
The adjusted shares began trading on Aug 28, 2023. This was SOBI's 3rd stock split, following the previous one in May 3, 2011.
1S9
Swedish Orphan Biovitrum AB (publ)
Glance View
Swedish Orphan Biovitrum AB (publ), often known as Sobi, navigates the intricate world of biopharmaceuticals with a singular focus on developing and delivering innovative treatments for rare diseases. Founded in the heart of Scandinavia, Sobi has crafted a unique niche by addressing medical needs that are often overlooked by larger pharmaceutical companies. The company specializes in hematology and immunology, focusing on conditions where it can leverage its expertise to make a tangible difference. With a robust pipeline of biopharmaceutical products, Sobi dedicates itself to research and partnerships that not only drive scientific advancements but also ensure that its therapies reach the global market. This mission aligns with its deep commitment to patients whose conditions lack effective treatments. Sobi’s business model thrives on a blend of strategic acquisitions, rigorous clinical development, and expansive distribution capabilities. By acquiring promising therapies and collaborating with other innovators in the biotech space, it continually expands its product portfolio and market reach. Revenue flows primarily from the sales of these specialized therapies, which command premium pricing due to their targeted nature and the complex manufacturing processes involved. The company also invests significantly in its research and development programs, channeling insights from its interactions with healthcare professionals and patients to optimize its offerings. Through its relentless focus on rare diseases, Sobi not only secures financial returns but also significantly impacts the quality of life for patients, staying true to its foundational ethos.
You don't have any saved screeners yet